Cleveland Biolabs (CBLI) 0.56 $CBLI
Cleveland BioLabs Announces Compensation Reductions for Co-Founders and Directors; New Board Nominees
Marketwire - Fri May 09, 7:02AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that two of the Company's co-founders, Chief Executive Officer, Yakov Kogan and Chief Scientific Officer, Andrei Gudkov and the Company's directors have voluntarily reduced their base pay by 20% in an effort to conserve financial resources. Co-founder reductions in base pay will take effect immediately and director reductions in base pay will become effective on July 1, 2014, following the election of directors at the annual stockholders meeting.
Cleveland BioLabs Reports First Quarter 2014 Financial Results and Development Progress
Marketwire - Thu May 08, 6:32AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2014.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014: 25 Company and 43 Drug Profiled
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pjhgmf/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - ActoKine Therapeutics - Aeolus Pharmaceuticals, Inc. - Biothera, Inc. - Bolder Biotechnology, Inc. - CEL-SCI Corporation - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Galera Therapeutics LLC - Gamida Cell Ltd. - HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG - Humanetics Corporation - ImmuneRegen BioSciences, Inc. - Meabco A/S - Midway Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Osiris Therapeutics, Inc. - Pluristem Therapeutics Inc. - ProCertus BioPharm Inc. - RxBio, Inc. - Soligenix, Inc. - Stealth Peptides Inc. - Terapio Corporation Drug Profiles: - remestemcel-L - entolimod - minocycline - NMIL-121 - BIO-300 - SGX-201 - GC-003 - Leukocyte Interleukin Injection - recilisib sodium - GC-4403 - NanoDTPA - SGX-202 - Homspera - rusalatide acetate - BP-C2 - romyelocel L - MTP-131 - BBT-045 - MDY-1001 - Radiogardase (Prussian Blue insoluble capsules) - JP4-039 - PLX-BMP - GC-4419 - Rx-100 - Stem Cell Therapy For Radiation Exposure - BIO-700 - BIO-800 - CLT-009 - PrC-210 - SY-303A For more information visit http://www.researchandmarkets.com/research/pjhgmf/radiation
Cleveland BioLabs to Report First Quarter 2014 Financial Results and Provide Operational Update on May 8
Marketwire - Tue Apr 29, 6:01AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on May 8, 2014, it will report its financial results for the first quarter ended March 31, 2014, and will host a conference call at 10:00 a.m. ET.
Global Bone Marrow Transplantation Therapeutic Pipeline Review
M2 - Mon Apr 28, 11:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lrc2d3/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - Allogeneic MPC For Bone Marrow Transplantation - melphalan - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation Companies Mentioned: - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. For more information visit http://www.researchandmarkets.com/research/lr...one_marrow
Thrombocytopenia Therapeutic Pipeline Review 2014 - Analysis of 20 Companies and 25 Drug Profiles
M2 - Mon Apr 28, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2wbjx/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - GlaxoSmithKline plc - BioLineRx, Ltd. - Eisai Co., Ltd. - Octapharma AG - Ono Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - Portola Pharmaceuticals, Inc. - Uni-Bio Science Group Ltd. - Cellerant Therapeutics, Inc. - Bolder Biotechnology, Inc. - Genelux Corporation - ViroMed Co., Ltd. - aTyr Pharma, Inc. - Neumedicines Inc. - Tarix Pharmaceuticals LTD. - STATegics, Inc. - Prophylix Pharma AS - InvivoGen Therapeutics - Myelo Therapeutics GmbH Drug Profiles - avatrombopag - lusutrombopag - immune globulin (human) - VM-501 - UNI-rhIL-11 - NL-201 - eltrombopag olamine - lusutrombopag - avatrombopag - ONO-7746 - GLONC-4 - CBLB-612 - BBT-030 - BBT-045 - NMIL-121 - PEG-VM501 - PanCyte - Tmax - Plasmid Gene Therapy For Chemotherapy-Induced Thrombocytopenia - BL-8040 - STST-4 - CLT-009 - PRT-060318 - Myelo-001 - Tromplate For more information visit http://www.researchandmarkets.com/research/z2...ocytopenia
Neutropenia Therapeutic Pipeline Review 2014 - Analysis of 16 Companies and 25 Drug Profiles
M2 - Mon Apr 28, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sl9vgd/neutropenia) has announced the addition of the "Neutropenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neutropenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neutropenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Hospira, Inc. - Gamida Cell Ltd. - Ligand Pharmaceuticals, Inc. - Cleveland BioLabs, Inc. - Telik, Inc. - ProMetic Life Sciences Inc. - Green Cross Corporation - Cellerant Therapeutics, Inc. - Genexine, Inc. - Bolder Biotechnology, Inc. - USV Limited - Pfenex Inc. - Mycenax Biotech Inc. - NAL Pharmaceuticals Ltd. - Inbiopro Solutions Pvt. Ltd. - Hanmi Pharmaceuticals, Co. Ltd. Drug Profiles - GCPGC - filgrastim biosimilar - MG-1107 - ezatiostat hydrochloride - HM-10460A - GC-003 - romyelocel L - Human Serum Albumin Fusion Protein Drug - GX-G3 - filgrastim - pegfilgrastim biosimilar - filgrastim biosimilar - CBLB-612 - PBI-4050 - BBT-015 - BBT-018 - BBT-007 - pegfilgrastim biosimilar - IBPB-004-IG - LG-7455 - ACN-8337 - pegfilgrastim biosimilar - Pegylated Granulocyte Colony Stimulating Factor Biosimilar - granulocyte colony-stimulating factor biobetter - Hemokine For more information visit http://www.researchandmarkets.com/research/sl...eutropenia
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Good News for Cleveland BioLabs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:20PM CDT
Cleveland BioLabs announced that it has achieved all objectives in a phase I trial on oncology candidate, CBL0102 (quinacrine).
Cleveland BioLabs Announces the Successful Completion of a Phase 1 Study of CBL0102
Marketwire - Wed Apr 16, 7:03AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the achievement of all objectives in a Phase 1 clinical trial of CBL0102, or quinacrine, an orally administered small molecule. The study was performed in patients with advanced cancers for which no standard care exists or which had become resistant to conventional therapies. All patients had tumors involving the liver.
Cleveland Biolabs Down 17.9%, Shares Slide into the Red (CBLI)
Comtex SmarTrend(R) - Tue Apr 15, 11:44AM CDT
Cleveland Biolabs (NASDAQ:CBLI) is one of today's worst performing penny stocks, down 17.9% to $0.55 on 1.0x average daily volume. Thus far today, Cleveland Biolabs has traded 767,000 shares, vs. average volume of 748,000 shares per day. The stock has underperformed the Dow (-17.9% to the Dow's -0.4%) and underperformed the S&P 500 (-17.9% to the S&P's -0.4%) during today's trading.
Karen Hughes Joins Omnia Biologics
PR Newswire - Tue Apr 08, 9:49AM CDT
Biologics development and manufacturing services provider Omnia Biologics, Inc. (Omnia) (Rockville, MD) today announced that Karen Hughes has joined the Omnia team as Senior Director of Quality Assurance and Quality Control.
CBL0137 Combination Studies to Be Presented at 2014 AACR Annual Meeting
Marketwire - Tue Apr 01, 7:03AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced two upcoming poster presentations at the 2014 American Association for Cancer Research (AACR) Annual Meeting, April 5-9, 2014 in San Diego, CA.
Cleveland Biolabs Up 13.4%, Penny Stock Attracts Attention (CBLI)
Comtex SmarTrend(R) - Thu Mar 20, 10:11AM CDT
Cleveland Biolabs (NASDAQ:CBLI) is one of today's best performing penny stocks, up 13.4% to $0.82 on 7.3x average daily volume. Cleveland Biolabs has traded 3.9 million shares thus far today, vs. average volume of 535,000 shares per day. The stock has outperformed the Dow (13.4% to the Dow's 0.3%) and outperformed the S&P 500 (13.4% to the S&P's 0.2%) during today's trading.
3 Stocks Under $10 Making Big Moves
at The Street - Wed Mar 19, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Cleveland BioLabs Reports Fourth Quarter and Fiscal 2013 Financial Results and Development Progress
Marketwire - Tue Mar 11, 6:30AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and fiscal year ended December 31, 2013.
Cleveland BioLabs to Host Fourth Quarter Earnings Webcast Live on Tuesday, March 11, 2014
ACCESSWIRE - Mon Mar 10, 1:06PM CDT
BUFFALO, NY / ACCESSWIRE / March 10, 2014 / Cleveland BioLabs (CBLI) will host a live webcast to discuss the results of the fourth quarter 2013, to be held Tuesday, March 11, 2014 at 10:00 AM Eastern Time.
5 Stocks Under $10 Setting Up to Soar
at The Street - Thu Feb 27, 12:54PM CST
These under-$10 stocks look ready to trade higher from current levels.
Cleveland BioLabs to Report Fourth Quarter and Fiscal 2013 Financial Results and Provide Operational Update on March 11
Marketwire - Thu Feb 27, 7:03AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on March 11, 2014, it will report its financial results for the fourth quarter and fiscal year ended December 31, 2013, and will host a conference call at 10:00 a.m. ET.
Bone Marrow Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8glf8/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. 'Bone Marrow Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Scope - A snapshot of the global therapeutic scenario for Bone Marrow Transplantation. - A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Bone Marrow Transplantation Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Bone Marrow Transplantation - Therapeutics Assessment Drug Profiles Allogeneic MPC For Bone Marrow Transplantation - Drug Profile melphalan - Drug Profile TM-400 - Drug Profile PLX-BMP - Drug Profile CBLB-612 - Drug Profile CBLB-612 - Drug Profile Perforin Inhibitor - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Mesoblast Limited Cleveland BioLabs, Inc. Pluristem Therapeutics Inc. Spectrum Pharmaceuticals, Inc. TikoMed AB For more information visit http://www.researchandmarkets.com/research/f8...one_marrow About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Cleveland BioLabs Announces Compensation Reductions for Co-Founders and Directors; New Board Nominees
Marketwire - Fri May 09, 7:02AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that two of the Company's co-founders, Chief Executive Officer, Yakov Kogan and Chief Scientific Officer, Andrei Gudkov and the Company's directors have voluntarily reduced their base pay by 20% in an effort to conserve financial resources. Co-founder reductions in base pay will take effect immediately and director reductions in base pay will become effective on July 1, 2014, following the election of directors at the annual stockholders meeting.
Cleveland BioLabs Reports First Quarter 2014 Financial Results and Development Progress
Marketwire - Thu May 08, 6:32AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2014.
Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014: 25 Company and 43 Drug Profiled
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pjhgmf/radiation) has announced the addition of the "Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - ActoKine Therapeutics - Aeolus Pharmaceuticals, Inc. - Biothera, Inc. - Bolder Biotechnology, Inc. - CEL-SCI Corporation - Cellerant Therapeutics, Inc. - Cleveland BioLabs, Inc. - Galera Therapeutics LLC - Gamida Cell Ltd. - HEYL Chemisch-pharmazeutische Fabrik GmbH und Co. KG - Humanetics Corporation - ImmuneRegen BioSciences, Inc. - Meabco A/S - Midway Pharmaceuticals, Inc. - Nanotherapeutics, Inc. - NeoStem, Inc. - Neumedicines Inc. - Onconova Therapeutics, Inc. - Osiris Therapeutics, Inc. - Pluristem Therapeutics Inc. - ProCertus BioPharm Inc. - RxBio, Inc. - Soligenix, Inc. - Stealth Peptides Inc. - Terapio Corporation Drug Profiles: - remestemcel-L - entolimod - minocycline - NMIL-121 - BIO-300 - SGX-201 - GC-003 - Leukocyte Interleukin Injection - recilisib sodium - GC-4403 - NanoDTPA - SGX-202 - Homspera - rusalatide acetate - BP-C2 - romyelocel L - MTP-131 - BBT-045 - MDY-1001 - Radiogardase (Prussian Blue insoluble capsules) - JP4-039 - PLX-BMP - GC-4419 - Rx-100 - Stem Cell Therapy For Radiation Exposure - BIO-700 - BIO-800 - CLT-009 - PrC-210 - SY-303A For more information visit http://www.researchandmarkets.com/research/pjhgmf/radiation
Cleveland BioLabs to Report First Quarter 2014 Financial Results and Provide Operational Update on May 8
Marketwire - Tue Apr 29, 6:01AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on May 8, 2014, it will report its financial results for the first quarter ended March 31, 2014, and will host a conference call at 10:00 a.m. ET.
Global Bone Marrow Transplantation Therapeutic Pipeline Review
M2 - Mon Apr 28, 11:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/lrc2d3/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. Companies Involved in Therapeutics Development - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. Drug Profiles - Allogeneic MPC For Bone Marrow Transplantation - melphalan - TM-400 - PLX-BMP - CBLB-612 - CBLB-612 - CGEN-15001 - Small Molecule to Inhibit Perforin for Bone Marrow Transplantation - Protein for Bone Marrow Transplantation Companies Mentioned: - Mesoblast Limited - Cleveland BioLabs, Inc. - Compugen Ltd. - Pluristem Therapeutics Inc. - Spectrum Pharmaceuticals, Inc. - TikoMed AB - Taiga Biotechnologies, Inc. For more information visit http://www.researchandmarkets.com/research/lr...one_marrow
Thrombocytopenia Therapeutic Pipeline Review 2014 - Analysis of 20 Companies and 25 Drug Profiles
M2 - Mon Apr 28, 3:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z2wbjx/thrombocytopenia) has announced the addition of the "Thrombocytopenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombocytopenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombocytopenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Thrombocytopenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Thrombocytopenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Thrombocytopenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Shionogi & Co., Ltd. - GlaxoSmithKline plc - BioLineRx, Ltd. - Eisai Co., Ltd. - Octapharma AG - Ono Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - Portola Pharmaceuticals, Inc. - Uni-Bio Science Group Ltd. - Cellerant Therapeutics, Inc. - Bolder Biotechnology, Inc. - Genelux Corporation - ViroMed Co., Ltd. - aTyr Pharma, Inc. - Neumedicines Inc. - Tarix Pharmaceuticals LTD. - STATegics, Inc. - Prophylix Pharma AS - InvivoGen Therapeutics - Myelo Therapeutics GmbH Drug Profiles - avatrombopag - lusutrombopag - immune globulin (human) - VM-501 - UNI-rhIL-11 - NL-201 - eltrombopag olamine - lusutrombopag - avatrombopag - ONO-7746 - GLONC-4 - CBLB-612 - BBT-030 - BBT-045 - NMIL-121 - PEG-VM501 - PanCyte - Tmax - Plasmid Gene Therapy For Chemotherapy-Induced Thrombocytopenia - BL-8040 - STST-4 - CLT-009 - PRT-060318 - Myelo-001 - Tromplate For more information visit http://www.researchandmarkets.com/research/z2...ocytopenia
Neutropenia Therapeutic Pipeline Review 2014 - Analysis of 16 Companies and 25 Drug Profiles
M2 - Mon Apr 28, 3:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sl9vgd/neutropenia) has announced the addition of the "Neutropenia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neutropenia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neutropenia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neutropenia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neutropenia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Companies Involved in Therapeutics Development - Hospira, Inc. - Gamida Cell Ltd. - Ligand Pharmaceuticals, Inc. - Cleveland BioLabs, Inc. - Telik, Inc. - ProMetic Life Sciences Inc. - Green Cross Corporation - Cellerant Therapeutics, Inc. - Genexine, Inc. - Bolder Biotechnology, Inc. - USV Limited - Pfenex Inc. - Mycenax Biotech Inc. - NAL Pharmaceuticals Ltd. - Inbiopro Solutions Pvt. Ltd. - Hanmi Pharmaceuticals, Co. Ltd. Drug Profiles - GCPGC - filgrastim biosimilar - MG-1107 - ezatiostat hydrochloride - HM-10460A - GC-003 - romyelocel L - Human Serum Albumin Fusion Protein Drug - GX-G3 - filgrastim - pegfilgrastim biosimilar - filgrastim biosimilar - CBLB-612 - PBI-4050 - BBT-015 - BBT-018 - BBT-007 - pegfilgrastim biosimilar - IBPB-004-IG - LG-7455 - ACN-8337 - pegfilgrastim biosimilar - Pegylated Granulocyte Colony Stimulating Factor Biosimilar - granulocyte colony-stimulating factor biobetter - Hemokine For more information visit http://www.researchandmarkets.com/research/sl...eutropenia
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Good News for Cleveland BioLabs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:20PM CDT
Cleveland BioLabs announced that it has achieved all objectives in a phase I trial on oncology candidate, CBL0102 (quinacrine).
Cleveland BioLabs Announces the Successful Completion of a Phase 1 Study of CBL0102
Marketwire - Wed Apr 16, 7:03AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced the achievement of all objectives in a Phase 1 clinical trial of CBL0102, or quinacrine, an orally administered small molecule. The study was performed in patients with advanced cancers for which no standard care exists or which had become resistant to conventional therapies. All patients had tumors involving the liver.
Cleveland Biolabs Down 17.9%, Shares Slide into the Red (CBLI)
Comtex SmarTrend(R) - Tue Apr 15, 11:44AM CDT
Cleveland Biolabs (NASDAQ:CBLI) is one of today's worst performing penny stocks, down 17.9% to $0.55 on 1.0x average daily volume. Thus far today, Cleveland Biolabs has traded 767,000 shares, vs. average volume of 748,000 shares per day. The stock has underperformed the Dow (-17.9% to the Dow's -0.4%) and underperformed the S&P 500 (-17.9% to the S&P's -0.4%) during today's trading.
Karen Hughes Joins Omnia Biologics
PR Newswire - Tue Apr 08, 9:49AM CDT
Biologics development and manufacturing services provider Omnia Biologics, Inc. (Omnia) (Rockville, MD) today announced that Karen Hughes has joined the Omnia team as Senior Director of Quality Assurance and Quality Control.
CBL0137 Combination Studies to Be Presented at 2014 AACR Annual Meeting
Marketwire - Tue Apr 01, 7:03AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) announced two upcoming poster presentations at the 2014 American Association for Cancer Research (AACR) Annual Meeting, April 5-9, 2014 in San Diego, CA.
Cleveland Biolabs Up 13.4%, Penny Stock Attracts Attention (CBLI)
Comtex SmarTrend(R) - Thu Mar 20, 10:11AM CDT
Cleveland Biolabs (NASDAQ:CBLI) is one of today's best performing penny stocks, up 13.4% to $0.82 on 7.3x average daily volume. Cleveland Biolabs has traded 3.9 million shares thus far today, vs. average volume of 535,000 shares per day. The stock has outperformed the Dow (13.4% to the Dow's 0.3%) and outperformed the S&P 500 (13.4% to the S&P's 0.2%) during today's trading.
3 Stocks Under $10 Making Big Moves
at The Street - Wed Mar 19, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Cleveland BioLabs Reports Fourth Quarter and Fiscal 2013 Financial Results and Development Progress
Marketwire - Tue Mar 11, 6:30AM CDT
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and fiscal year ended December 31, 2013.
Cleveland BioLabs to Host Fourth Quarter Earnings Webcast Live on Tuesday, March 11, 2014
ACCESSWIRE - Mon Mar 10, 1:06PM CDT
BUFFALO, NY / ACCESSWIRE / March 10, 2014 / Cleveland BioLabs (CBLI) will host a live webcast to discuss the results of the fourth quarter 2013, to be held Tuesday, March 11, 2014 at 10:00 AM Eastern Time.
5 Stocks Under $10 Setting Up to Soar
at The Street - Thu Feb 27, 12:54PM CST
These under-$10 stocks look ready to trade higher from current levels.
Cleveland BioLabs to Report Fourth Quarter and Fiscal 2013 Financial Results and Provide Operational Update on March 11
Marketwire - Thu Feb 27, 7:03AM CST
Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that on March 11, 2014, it will report its financial results for the fourth quarter and fiscal year ended December 31, 2013, and will host a conference call at 10:00 a.m. ET.
Bone Marrow Transplantation - Pipeline Review, H1 2014 Research Report
M2 - Mon Feb 24, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/f8glf8/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H1 2014" report to their offering. 'Bone Marrow Transplantation - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Bone Marrow Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation. Scope - A snapshot of the global therapeutic scenario for Bone Marrow Transplantation. - A review of the Bone Marrow Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Bone Marrow Transplantation pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Bone Marrow Transplantation Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Bone Marrow Transplantation - Therapeutics Assessment Drug Profiles Allogeneic MPC For Bone Marrow Transplantation - Drug Profile melphalan - Drug Profile TM-400 - Drug Profile PLX-BMP - Drug Profile CBLB-612 - Drug Profile CBLB-612 - Drug Profile Perforin Inhibitor - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Mesoblast Limited Cleveland BioLabs, Inc. Pluristem Therapeutics Inc. Spectrum Pharmaceuticals, Inc. TikoMed AB For more information visit http://www.researchandmarkets.com/research/f8...one_marrow About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
